Bayer (FRA:BAYN) received a €118.00 ($145.68) target price from stock analysts at Berenberg Bank in a research note issued on Monday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Berenberg Bank’s price target points to a potential upside of 20.64% from the stock’s current price.
BAYN has been the subject of a number of other reports. Citigroup reiterated a “buy” rating on shares of Bayer in a research note on Friday, February 16th. Nord/LB reissued a “neutral” rating on shares of Bayer in a report on Wednesday, December 27th. DZ Bank reissued a “buy” rating on shares of Bayer in a report on Monday, December 11th. UBS Group reissued a “buy” rating on shares of Bayer in a report on Monday, January 15th. Finally, Deutsche Bank set a €125.00 ($154.32) price objective on Bayer and gave the company a “buy” rating in a report on Friday, January 19th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. Bayer presently has a consensus rating of “Buy” and a consensus target price of €119.14 ($147.08).
Shares of Bayer (FRA BAYN) opened at €97.81 ($120.75) on Monday. Bayer has a 12 month low of €91.58 ($113.06) and a 12 month high of €123.82 ($152.86). The company has a market capitalization of $81,380.00 and a PE ratio of 26.29.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.